Clinical trials
Recurrent High Grade Glioma clinical trials
Below are recruiting recurrent high grade glioma clinical trials, each written for real people, not researchers. We’re tracking 77 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05096481RecruitingPhase 2
Vaccine for brain tumors in children and young adults
This trial tests a vaccine that may help the immune system fight brain tumors (medulloblastoma, high-grade glioma, and DIPG). It is for patients who have already had standard treatment and whose tumors are still present or have returned.
Aurora, ColoradoAges 3–39 - NCT04485559RecruitingPhase 1
Trametinib and everolimus for recurrent gliomas
This trial tests two drugs, trametinib and everolimus, for children and young adults with recurrent or progressive gliomas (a type of brain tumor). The goal is to see if this drug combination is safe and effective in treating these tumors.
Birmingham, AlabamaAges 1–25 - NCT07544992RecruitingPhase 1
CAR T Cells for Recurrent High-Grade Brain Tumors
This trial tests genetically engineered immune cells (CAR T cells) injected directly into the brain to treat recurring or worsening high-grade gliomas. The cells are designed to recognize and attack tumor cells that have specific markers (EGFR and IL13Rα2).
Duarte, CaliforniaAges 18 years+ - NCT06660056RecruitingPhase 1
GC001 injection for returning or growing high-grade brain tumors
This trial tests a new drug, GC001, injected directly into the tumor in people with high-grade gliomas (WHO grade 3 or 4) that have come back or are growing. It may be an option if standard treatments have stopped working.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06253234RecruitingPhase 1
DC vaccine for recurrent high-grade gliomas
This trial tests a vaccine made from your own immune cells (dendritic cells) to see if it can help control recurrent or progressive high-grade gliomas. It is for people whose brain tumor has returned after standard treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT06018363RecruitingPhase 1/Phase 2
Cell therapy for recurrent high-grade glioma
This trial tests a new cell therapy (QH104) for people with an aggressive brain tumor called high-grade glioma that has come back or worsened after standard treatment. The therapy targets a specific protein (B7-H3) on tumor cells to try to fight the cancer.
Suzhou, JiangsuAges 18–70 - NCT07655869RecruitingEarly Phase 1
Lu177-DOTA-EB-RGD2 therapy for returning high-grade glioma
This trial tests a radioactive drug that targets a protein on tumor blood vessels to treat glioblastoma that has come back after standard treatment. It may help shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07416188RecruitingPhase 1/Phase 2
LMP744 drug for returning glioblastoma
This trial tests an experimental drug called LMP744 for people whose glioblastoma has come back. It aims to see if the drug can slow or stop tumor growth by targeting specific proteins in cancer cells.
Bethesda, MarylandAges 18–99 - NCT05278208RecruitingPhase 1/Phase 2
Lutathera for high-grade brain tumors that returned or got worse
This trial tests if Lutathera, a radioactive drug that targets certain tumors, can help children and young adults with high-grade brain tumors or meningiomas that have come back or are growing. It aims to see if the treatment is safe and works.
Aurora, ColoradoAges 4–39 - NCT07710690RecruitingPhase 1
Study of NRG-103 injection for recurrent high-grade glioma
This trial tests a new injection called NRG-103 for people whose high-grade glioma (a fast-growing brain tumor) has come back after standard treatments. The goal is to see if it's safe and if it might help shrink the tumor.
ShanghaiAges 18 years+ - NCT03896568RecruitingPhase 1
Trial of stem cell therapy for recurrent high-grade brain tumors
This Phase 1 study tests an advanced stem-cell treatment (hMSC-DNX2401) for recurrent high-grade glioma, including certain brain tumor types that come back. It aims to see if the treatment can be safely delivered and whether it can help control the tumor after standard therapies have already been tried.
Houston, TexasAges 18 years+ - NCT04099797RecruitingPhase 1
CAR T therapy for certain GD2 brain tumors
This Phase 1 study tests CAR T cells designed to target a marker called GD2 on brain tumors. It aims to see if the treatment is safe and whether it can shrink or control these tumors in children and young adults.
Houston, TexasAges 1–25 - NCT04573140RecruitingPhase 1
RNA vaccine study for newly diagnosed adult and pediatric brain tumors
This Phase 1 trial studies an “RNA-lipid particle” vaccine given after surgery for certain newly diagnosed brain cancers (glioblastoma in adults, high-grade glioma in children/teens). The goal is to see whether the vaccine is safe and can train the immune system to fight the tumor.
Washington D.C., District of ColumbiaAges 4 years+ - NCT05532397Recruiting
Tested lab-chosen drug combo for recurrent brain tumor
This study uses a patient’s tumor tissue to test drug combinations in the lab, aiming to help choose a better second-line treatment for recurrent high-grade astrocytic glioma. If your tumor tissue can be tested, the results may guide a more personalized medication plan.
SingaporeAges 21–99 - NCT05632562RecruitingEarly Phase 1
PET/MRI scan study for newly diagnosed brain cancer changes
This early-phase study uses special PET/MRI scans to look at how a newly diagnosed high-grade glioma is changing under standard treatment. The goal is to see whether these scans can better assess the disease, which may help guide future care.
Birmingham, AlabamaAges 10–89 - NCT05698524RecruitingPhase 1
Temodar plus an investigational pill for recurrent brain cancer
This Phase 1 study tests an investigational drug (PCI-24781) together with Temodar in people whose high-grade glioma (grade III/IV) has come back after prior treatment. It aims to find a safe dose and see how well the combination may work for recurrent disease.
Omaha, NebraskaAges 19 years+ - NCT05917145RecruitingPhase 1
Drug WSD0628 plus radiation for recurrent brain tumor
This Phase 1 trial tests a new cancer drug (WSD0628) given with radiation for people whose high-grade glioma has returned after prior treatment. The goal is to find a safe dose and see how well the treatment works in this situation.
Rochester, MinnesotaAges 18 years+ - NCT05979064Recruiting
Belly fat graft for recurrent brain tumor
This study tests if a piece of your own belly fat (omentum) placed in the brain during tumor surgery can help fight recurrent glioblastoma. It is for people who are already scheduled for surgery to remove their brain tumor.
New York, New YorkAges 18 years+ - NCT06011109RecruitingPhase 1/Phase 2
APG-157 plus Avastin for recurrent high-grade glioma
This trial tests a combination of two drugs—APG-157 (an oral plant-based medicine) and bevacizumab (Avastin)—for people with recurrent high-grade brain tumors that have already been treated with standard therapies. The goal is to see if adding APG-157 can help control the tumor better.
Rochester, MinnesotaAges 19 years+ - NCT06072586RecruitingEarly Phase 1
Study of BDTX-1535 for brain tumors with EGFR changes
This trial tests a new drug, BDTX-1535, for people with a type of brain tumor called high-grade glioma that has a specific change in the EGFR gene. The study looks at how the drug works in the body and how safe it is for both newly diagnosed and recurrent tumors.
Chandler, ArizonaAges 18 years+ - NCT06126744RecruitingPhase 1
Study of a virus therapy for recurrent brain cancer
This trial tests a virus-based treatment called MVR-C5252 for people whose high-grade glioma or glioblastoma has come back after standard therapy. The virus is injected directly into the tumor to try to kill cancer cells and boost the immune system. The goal is to see if it is safe and if it can shrink the tumor.
New York, New YorkAges 18 years+ - NCT06160206RecruitingPhase 2
Study of retifanlimab, bevacizumab, and radiation for recurrent glioblastoma
This trial tests a combination of immunotherapy (retifanlimab), a targeted drug (bevacizumab), and low-dose radiation for people whose glioblastoma has come back. The goal is to see if this treatment can help shrink or slow the tumor.
Scottsdale, ArizonaAges 18 years+ - NCT06161610Recruiting
Laser treatment for returning high-grade glioma
This study tests a laser ablation treatment for people whose high-grade glioma (a fast-growing brain tumor) has come back after standard therapy. The goal is to see if this minimally invasive laser procedure can help control the tumor.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06264388RecruitingPhase 2
Gene therapy plus oral drug for recurrent brain tumors
This trial tests a two-part treatment: an injected virus (DB107-RRV) plus an oral medication (DB107-FC) for people whose high-grade glioma (a type of brain tumor) has come back. The virus is designed to deliver a gene that makes the tumor sensitive to the oral drug, which then helps kill the cancer cells.
Miami, FloridaAges 18–75
Hear when a new Recurrent High Grade Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent high grade glioma?
- Yes. Clin2 currently lists 77 recruiting recurrent high grade glioma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent high grade glioma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent high grade glioma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.